Ronald Fisher Is Not Being ‘Cancelled’, But His Eugenic Advocacy Should Have Consequences
By Eric Michael Johnson,
This View of Life
| 04. 12. 2021
Photo by Schutz, stained glass designed by Maria McClafferty,
CC BY-SA 2.5, via Wikimedia Commons
While Black Lives Matter protests raged and confederate statues were toppled across the United States following the killing of George Floyd, the quiet removal of a stained-glass window at Cambridge University closed one chapter in the history of scientific racism. On June 26, 2020, a commemorative window in honor of the statistician, geneticist, and evolutionary biologist Ronald Aylmer Fisher was targeted for removal from Gonville and Caius College where he had lived during his time at Cambridge.1 A student petition that had received more than 1,400 signatures objected to Fisher’s “endorsements of colonialism, white supremacy and eugenics.”2 Following a review, the College Council decided to support the students with a statement acknowledging Fisher’s fundamental contributions to statistics and genetics but concluded that honoring him would not constitute a welcoming environment given that he was “a prominent proponent of eugenics, both in his scientific work and his public pronouncements throughout his career.”3 Other organizations, such as the Society for the Study of Evolution...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...